Prompt antifungal therapy (do not wait for culture confirmation)
Surgical debridement of necrotic tissue
Reversal of underlying immunodeficiency
Correction of metabolic abnormalities (DKA, hyperglycemia)
Antifungal choice rationale
Liposomal formulation preferred over conventional amphotericin B deoxycholate
Superior tissue penetration in infected necrotic tissue
Significantly lower nephrotoxicity
Higher doses achievable
Triazole spectrum: posaconazole and isavuconazole active; voriconazole inactive
Echinocandins lack cell wall target (Mucorales have minimal 1,3-beta-D-glucan)
Combination antifungal therapy
L-AmB plus isavuconazole or posaconazole used at some centers
No RCT data; expert opinion; consider in refractory or cerebral cases
Monitoring for treatment response
Clinical: resolution of fever, edema, stabilization of vision
Imaging: weekly CT or MRI in unstable patients; monthly thereafter
Improvement on imaging in mucormycosis is slow — do not discontinue early based on persistent changes
Serum Mucorales PCR may be useful for monitoring treatment response
Patient Discharge Instructions
copy discharge instructions
Discharge instructions for Mucormycosis (Rhino-orbital-cerebral)
About your infection
You have been treated for a serious fungal infection of your sinuses, eye area, or brain called mucormycosis
This infection requires prolonged treatment, usually several months
Strict control of your blood sugar is essential to prevent the infection from returning
Your antifungal medication
Take all antifungal medications exactly as prescribed
Do not stop taking antifungal medication without consulting your doctor, even if you feel better
Report any new nausea, vomiting, jaundice, or decreased urine output to your doctor immediately
Blood sugar control
Check your blood glucose as directed and keep a log
Follow your diabetic diet and take all diabetes medications
High blood sugar can allow this infection to return
Follow-up appointments
You must attend all scheduled follow-up appointments with infectious disease, ENT surgery, and eye specialist
Imaging (CT scan or MRI) will be repeated regularly to monitor your response to treatment
Do not miss appointments — this infection can return or worsen rapidly
Return to emergency department immediately for
Any new or worsening facial pain, numbness, or swelling
Any change in vision including blurring, double vision, or loss of vision
New headache that is severe or different from prior headaches
Confusion, difficulty speaking, seizures, or weakness in any limb
Fever above 38.5 degrees Celsius
New black or dark discoloration inside the nose or mouth
Any wound breakdown or new skin discoloration at surgical site
References
Guidelines and key sources
Kontoyiannis DP, Walsh TJ
Mucormycosis. New England Journal of Medicine. 2026
NEJM comprehensive review: clinical spectrum, diagnostics, and management
Cornely OA, Alastruey-Izquierdo A, et al
Global Guideline for the Diagnosis and Management of Mucormycosis: ECMM/MSGERC Initiative
Lancet Infectious Diseases. 2019
Core international guideline for antifungal selection and surgical approach
Zia Z, Sajadi MJ, et al
Survival and Prognostic Factors in Rhino-Orbito-Cerebral Mucormycosis: A 3-Year Cohort Study
Scientific Reports. 2025
Mortality data by anatomic extent; orbital exenteration survival outcomes
Douglas AP, Lamoth F, John TM, et al
ASTCT Series: Management and Prevention of Non-Aspergillus Molds in HCT Recipients
Transplantation and Cellular Therapy. 2025
HCT-specific risk period and antifungal management
Kozan G, Dedeoğlu S, et al
Impact of Anatomical Extent and Combined Surgical-Medical Therapy on Survival in Sinonasal and ROCM: A 14-Year Retrospective ENT Cohort
Journal of Clinical Medicine. 2025
Surgical debridement mortality reduction data
Brown L, Tschiderer L, Alanio A, et al
Diagnosis of Mucormycosis by PCR: Systematic Review and Meta-Analysis
EClinicalMedicine. 2025
Mucorales PCR sensitivity and performance data
Gervais M, Aubertin M, Verillaud B, et al
Systematic Surgical Reassessment Combined With Liposomal Amphotericin B: The MICA Protocol
Acta Oto-Laryngologica. 2026
Second-look surgery protocol evidence
Groll AH, Castagnola E, Cesaro S, et al
ECIL-4 Guidelines for Invasive Fungal Diseases in Pediatric Patients
Lancet Oncology. 2014
Pediatric antifungal dosing and management framework
Sweet R, Hovenden M, Harvey CE, et al
Rhino-Orbital Cerebral Mucormycosis in a Diabetic Patient: An Emergency Medicine Case Report
Journal of Emergency Medicine. 2023
ED recognition and management framework
Czech MM, Cuellar-Rodriguez J
Mucormycosis. Infectious Disease Clinics of North America. 2025
Comprehensive clinical review including pathophysiology and therapeutic considerations
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.